Portolano Cavallo

Life Sciences


18 Apr
Chatbots and virtual assistants: How might they be used in pharmaceuticals?
When browsing the web and using smartphone applications, users increasingly encounter chatbots and virtual assistants (some more sophisticated than others) that interact with them and generate conversations This is in part due to the development and implementation of artificial intelligence systems.
3 Apr
Article 22 EUMR is still up in the air: Advocate General’s opinion in the Illumina/Grail saga
Advocate General Nicholas Emiliou advised setting aside the General Court’s judgment and annulling the decision of the European Commission to accept the request from certain Member States to review the transaction under Article 22 of the EUMR.
19 Jan
Recent legislative news in the life sciences sector under the Budget Law
The so-called “Budget Law” for 2024 wields significant impact on the life sciences sector, and allocates to the healthcare sector EUR 3 billion for 2024, EUR 4 billion for 2025, and EUR 4.2 billion for 2026.
3 Nov 23
The digital caregiver: Insights from the 4th AFI Patient Day
The term caregiver is commonly used to identify a person who provides day-to-day care for someone who is not self-sufficient. This may be a family member of the patient or a paid person.
21 Sep 23
Whistleblowing Decree: Key points for the pharmaceutical sector
Large multinational companies are being called to assess the compatibility of existing reporting channels with the requirements of the new regulation published on March 15, 2023 on the Official Journal of the Italian Republic, implementing the EU Directive 2019/1937 on whistleblowing.
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new digital channels
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on